Linked research, clinical, and regulatory source pathways.
Company profile
About Caris Life Sciences
Caris Life Sciences is a next-generation AI TechBio company and precision medicine pioneer founded in 2008 with the mission to improve the human condition. The company revolutionizes cancer care by providing physicians and patients with comprehensive molecular profiling services that analyze cancer at the DNA, RNA, and protein levels. Caris has built one of the world's largest multimodal databases, containing over 790,000 matched patient records combining molecular and clinical outcomes data. The company's flagship products include MI Profile for tissue-based whole exome and whole transcriptome sequencing, Caris Assure for blood-based profiling, and AI-powered solutions like Caris GPSai and Caris FOLFIRSTai. Through the Caris Precision Oncology Alliance, the company collaborates with over 95 leading cancer institutions worldwide, including 45+ NCI-designated cancer centers, to advance precision oncology research and clinical care. Caris serves the full cancer care continuum from disease detection through therapy selection to treatment monitoring, supporting oncologists, health systems, biopharma companies, and research institutions globally.
Company description Caris Life Sciences official website
Mission. Caris was built for one reason — to improve the human condition. Through tireless efforts, breakthrough molecular science, and a passionate commitment to quality, we remain steadfastly focused on the most important part of our work — the patient.
Primary marketPathology & Laboratory Diagnostics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Caris Life Sciences?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Breast cancer
- Central nervous system tumors
- Cutaneous malignancies
- Gastrointestinal cancers
- Genitourinary cancers
- Gynecologic malignancies
- Neuroendocrine tumors
- Pan-cancer
- Sarcoma
- Thoracic cancers
Who it serves
- Biopharma companies
- Cancer centers
- Health systems
- Oncologists
- Pathology practices
- Research institutions
Deployment & integration
Deployment information is currently being developed.
Recorded integration context: EHR systems, Multiple Electronic Health Record platforms for ordering and results viewing.
Geographic context
MarketsInternational markets through distributors · United States
Company sourceOfficial website
Company milestones
Platform expansion
Announced dual listing on NYSE Texas (June 2026), announced share repurchase program (June 2026), expanded database to 790,000+ matched patient records
Partnerships
Recorded partners
- 45+ NCI-designated cancer centers
- Caris Precision Oncology Alliance with 95+ member institutions
- EHR integration partners
- International distributors globally
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
No source-backed Company products are currently listed.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Distinct genomic landscapes of mismatch-repair deficiency (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancer depending on tumor mutation burden (TMB) levels.Journal for immunotherapy of cancer · Oct 15, 2026
Differential impact of tumor-derived ESR1 mutations on elacestrant benefit in metastatic breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · Oct 13, 2026
The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial.Nature communications · Oct 9, 2026
FGFR2/3-Altered Intrahepatic Cholangiocarcinoma: A Distinct Clinicopathologic and Molecular Subtype Associated with Improved Disease-Specific Survival.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · Oct 5, 2026
Sinonasal POU2AF3 (COLCA2)-rearranged carcinomas: a study of 11 aggressive tumors with findings supporting classification as solid adenoid cystic carcinoma.Virchows Archiv : an international journal of pathology · Sep 23, 2026
Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge.Journal of neuro-oncology · Sep 16, 2026
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
790,000+ matched molecular and clinical outcomes records
World's largest multimodal database
1.0+ million cases processed
Total testing volume
6.5+ million tests performed
Cumulative testing experience
50+ billion molecular markers measured
Depth of molecular analysis
23,000 gene coverage
Comprehensive genomic profiling
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Caris Life Sciences
Recent articles published on Caris Life Sciences's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Pathology & Laboratory Diagnostics
Companies applying AI to digital pathology, histopathology slide analysis, laboratory diagnostics, or biomarker discovery. Includes AI-powered interpretation of lab test results, at-home diagnostic devices with AI analysis, and platforms that analyze tissue samples or biological specimens to support clinical diagnosis.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.